Non-enrolment of ovarian cancer patients in clinical trials: reasons and background
Annals of OncologyPublished 9 August 2005Open access
Philipp Harter, Andreas du Bois, Carmen Schade‐Brittinger, Alexander Burges, K. Wollschlaeger, M. Gropp
Citations43
SJR quartileQ1
SJR score19.07
SNIP10.48
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
The results suggest that at least some inclusion criteria for clinical trials should be modified to increase study participation without compromising safety.
Abstract
Study patients differ substantially from non-study patients, thus hampering generalisation of study results. Our results suggest that at least some inclusion criteria for clinical trials should be modified to increase study participation without compromising safety.
Keywords
MathematicsMedicineBiochemistry, Genetics and Molecular Biology
The LancetThe CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials
5,372 Citations2001David Moher, Kenneth F. Schulz +1 more
The revised CONSORT statement presented here incorporates new evidence and addresses some criticisms of the original statement to improve the reporting of an RCT, enabling readers to understand a trial's conduct and to assess the validity of its results.
New England Journal of MedicineUnderrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
2,177 Citations1999Laura F. Hutchins, Joseph M. Unger +3 more
There is substantial under representation of patients 65 years of age or older in studies of treatment for cancer, and the reasons should be clarified, and policies adopted to correct this underrepresentation.
Journal of Clinical OncologyParticipation of Patients 65 Years of Age or Older in Cancer Clinical Trials
1,043 Citations2003Joy H. Lewis, Meredith L. Kilgore +6 more
The elderly are underrepresented in cancer clinical trials relative to their disease burden, and older patients are more likely to have medical histories that make them ineligible for clinical trials because of protocol exclusions.
Journal of Clinical EpidemiologyBarriers to Participation in Randomised Controlled Trials
912 Citations1999Sue Ross, Adrian Grant +4 more
To overcome barriers to clinician recruitment, the trial should address an important research question and the protocol and data collection should be as straightforward as possible.
Journal of Clinical OncologyProspective Evaluation of Cancer Clinical Trial Accrual Patterns: Identifying Potential Barriers to Enrollment
603 Citations2001Primo N. Lara, Roger Higdon +14 more
Barriers to cancer clinical trial accrual can be prospectively identified and addressed in the development and conduct of future studies, which may potentially lead to more robust clinical trials enrollment.
The LancetComparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review
362 Citations2004Jeffrey Peppercorn, Jane C. Weeks +2 more
There is insufficient data to conclude that such a trial effect exists, but patients with cancer should be encouraged to enroll in clinical trials on the basis of trials' unquestioned role in improving treatment for future patients.
Annals of OncologyAdvanced epithelial ovarian cancer: 1993 consensus statements
185 Citations1993Darlene Allen, J. Baak +28 more
A group of specialists in the field of ovarian cancer reached consensus on a number of issues with implications for standard practice and for research of advanced epithelial ovarian cancer, and cisplatin plus paclitaxel has been shown to be superior to previous standard therapy in previously untreated advanced ovarian cancer.
CancerSurvey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials
181 Citations2002Alice B. Kornblith, Margaret Kemeny +9 more
Barriers to accruing eligible older patients to clinical trials were obtained from the physician's perspective for cancer and Leukemia Group B trial 9670.
Journal of Clinical OncologyFactors Associated With Breast Cancer Clinical Trials Participation and Enrollment at a Large Academic Medical Center
167 Citations2004Michael S. Simon, Wei Du +6 more
The practice patterns of medical oncologists at a large National Cancer Institute Comprehensive Cancer Center in Detroit, MI were evaluated to better understand factors associated with accrual to breast cancer clinical trials.
Social Science & MedicineAccrual to cancer clinical trials: Directions from the research literature
164 Citations1991Carolyn Gotay
Analysis of the research literature on accrual to cancer therapy trials shows that nonparticipation is influenced by physician and patient variables, as well as by characteristics of the specific protocols.
CancerParticipants in prospective, randomized clinical trials for resected non-small cell lung cancer have improved survival compared with nonparticipants in such trials
154 Citations1985Scott Davis, Peter Wright +10 more
The survival of trial patients is significantly better than that of controls and the possibility that inclusion in these controlled cancer trials may have had an inherent advantage for all participants is suggested.
Journal of Clinical OncologySelection bias in clinical trials.
150 Citations1985Karen H. Antman, Dante Amato +8 more
In this study, the randomized and nonrandomized series yielded differing conclusions regarding treatment efficacy, even when an adjustment was made for known prognostic facts.
Journal of Clinical OncologyFundamental dilemmas of the randomized clinical trial process: results of a survey of the 1,737 Eastern Cooperative Oncology Group investigators.
147 Citations1994Kathryn M. Taylor, Michael Feldstein +4 more
Questions are raised regarding the perceived generalizability of trial findings, the role of end points other than survival for clinical trials, the consequences of physician overestimation of patient accrual, and the impact of randomized trials on the behavior of clinicians.
Journal of Clinical OncologyWhy Cancer Patients Enter Randomized Clinical Trials: Exploring the Factors That Influence Their Decision
138 Citations2004James R. Wright, Timothy J. Whelan +9 more
Strategies that better address the potential benefits of trial entry may result in improved accrual and interventions or aids that focus on the supportive aspects of the decision-making process while respecting the need for information and patient autonomy may also lead to meaningful improvements in accruals.
Gynecologic OncologyLong-Term Results and Prognostic Factors in Patients with Epithelial Ovarian Cancer
134 Citations2000J.-L. Brun, Anne Feyler +4 more
The study confirms the benefit of cytoreductive surgery and the efficacy of platinum plus paclitaxel first-line chemotherapy which has recently been recognized as the standard treatment for advanced epithelial ovarian cancer.
CancerAnalysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma
134 Citations2001Catherine Mayers, Tony Panzarella +1 more
Treatment‐related factors that might influence survival after adjuvant treatment for breast carcinoma include treatment as part of a clinical trial, toxicity of treatment, the regimen and schedule used, and dose intensity.
Journal of Clinical OncologyAdjuvant Chemotherapy for Breast Cancer: How Presentation of Recurrence Risk Influences Decision-Making
88 Citations2003Celia Chao, Jamie L. Studts +7 more
The hypothesis that the method used to present information about chemotherapy influences treatment decisions is supported, as absolute survival benefit is the most easily understood method of conveying the information regarding benefit of treatment.
Annals of OncologyAdvanced epithelial ovarian cancer: 1998 consensus statements
86 Citations1999J. S. Berek, K. Bertelsen +28 more
One of the major conclusions drawn by the consensus committee was that in previously untreated advanced ovarian cancer, cisplatin plus paclitaxel has been shown to be superior to previous standard therapy with cisPlatin plus cyclophosphamide (level I evidence).
Journal of Clinical EpidemiologyA Study in Contrasts: Eligibility Criteria in a Twenty-Year Sample of NSABP and POG Clinical Trials
79 Citations1998Abraham Fuks, Charles Weijer +4 more
The difference between NSABP studies (explanatory trials) and POG studies (pragmatic trials) suggest that large numbers of eligibility criteria are not necessary for quality studies, and the inclusion/exclusion criteria distinction be abandoned.
Annals of OncologySmall-cell lung cancer: Patients included in clinical trials are not representative of the patient population as a whole
77 Citations1999Vincent Cottin, D. Arpin +5 more
The subgroup of patients included in the trials was not representative of the patient population as a whole because of restrictive eligibility criteria and the proportion and major characteristics of ineligible and non-participating patients be mentioned in any publication of a clinical trial.
CancerFactors that influence the recruitment of patients to Phase III studies in oncology
68 Citations2002James R. Wright, Dauna Crooks +3 more
The current study was initiated to explore the factors that influence the decision of patients with cancer regarding clinical trial entry, specifically from the perspective of the CRA.
British Journal of HaematologyImpact of active and passive exclusions on the results of a clinical trial in multiple myeloma
55 Citations1992Martin Hjorth, Erik Holmberg +3 more
During the 3 years 1984–86, 314 cases of multiple myeloma were diagnosed in the Health Care Region of Western Sweden, 180 of these cases were included in a clinical trial and 14 were diagnosed post mortem.
Acta OncologicaSmall-Cell Lung Cancer in the Elderly: Is Age of Patient a Relevant Factor?
55 Citations1999José Jara
Carefully calculated dose reductions for chemotherapy in elderly patients based on initial performance status and/or toxicity during treatment may be a useful policy without detrimental implications on outcome.
Gynecologic OncologyAn assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study
43 Citations2004David H. Moore, James Kauderer +3 more
Age appears to be an important factor influencing treatment selection among patients with stage III/IV ovarian cancer, and practitioners' attitudes should be monitored to assure that elderly patients are not inappropriately denied participation in GOG clinical trials.
Acta OncologicaSelection of Patients may Limit the Generalizability of Results from Cancer Trials
37 Citations2002Sophie D. Fosså, Eva Skovlund
By registering patients undergoing comparable treatment outside a trial, the overall applicability of the treatment in question can be assessed and differences in overall as well as cancer-specific survival could be demonstrated.
Geburtshilfe und FrauenheilkundeDie Therapie des fortgeschrittenen Ovarialkarzinoms in Deutschland: Welchen Einfluss hat die Teilnahme an klinischen Studien? - Ergebnisse einer Umfrage der ORGANKOMMISSION OVAR der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) in der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) und der Deutschen Krebsgesellschaft (DKG) -
21 Citations2001Andreas du Bois, Jacobus Pfisterer +2 more
British Journal of CancerProtocol allocation and exclusion in two Danish randomised trials in ovarian cancer
18 Citations1991K. Bertelsen
The experience from this study is: only essential and simple questions should be examined in multicentre trials and the participation of departments only randomising a small and selected part of their patients is questionable.
JNCI Journal of the National Cancer InstituteTrial Data Lacking For Elderly Patients With Breast Cancer
9 Citations2000Norma J. Nelson